About Us

The safescimet programme was established as a IMI (Innovative Medicines Initiative) Education and Training programme for safety scientists, or others working in drug discovery and development, who want to strengthen their professional area of expertise, including professionals at the start of their industry career. safescimet provides education and training in Safety Sciences leading to a new generation of safety specialists with strong competencies in integrative and translational medicines research and development. The programme also includes application of novel technologies in risk assessment. This will allow holistic and critical evaluations of the safety of drug candidates and new medicines by linking in vitro and in vivo data with patient data more effectively. Since 2017 the University of Konstanz is leading partner of the safescimet education programme under the responsibility of Prof Dr Daniel Dietrich.

Scope and objectives

safescimet constitutes a new and unique pan-European education and training network, developing and establishing a comprehensive Modular Education and Training Programme in Safety Sciences for Medicines. This programme  addresses the needs in small and large pharmaceutical companies, regulatory authorities, academic institutes and health care. The network, bringing together top institutions for drug safety education, training and research with pharmaceutical industry leaders, creates the new type, high quality and sustainable programme. The tailor-made courses encompass safety, ethical, regulatory and societal aspects in all phases of drug development, with emphasis on holistic, integrative, translational and 3Rs aspects of drug safety assessment.

Impact of safescimet

  • Consolidated public-private partnership and institutional collaboration in providing cutting-edge science education and training.
  • New and sustainable cooperative European Advanced Master’s Programme in Safety Sciences for Medicines.
  • Same master’s level courses available and accessible for personal continuing professional development (CPD) among safety scientists.
  • Reduced costs for drug discovery and development and accelerated  innovation in the pharmaceutical industry.
  • Reduction of adverse drug effects in the clinical research phases.
  • Generally improved medicines safety evaluation, including in regulatory procedures.
  • Improved quality of life for the European citizen since contributing to the introduction of new, better and safer medicines.